Filing Details

Accession Number:
0001209191-15-058922
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-07-02 16:42:31
Reporting Period:
2015-07-01
Filing Date:
2015-07-02
Accepted Time:
2015-07-02 16:42:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1117480 Chimerix Inc CMRX Pharmaceutical Preparations (2834) 330903395
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1198230 J Martha Demski C/O Chimerix, Inc.
2505 Meridian Parkway, Suite 340
Durham NC 27713
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-07-01 2,000 $1.53 2,000 No 4 M Direct
Common Stock Disposition 2015-07-01 1,300 $45.70 700 No 4 S Direct
Common Stock Disposition 2015-07-01 700 $46.63 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2015-07-01 2,000 $0.00 2,000 $1.53
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,126 2018-06-25 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 14,788 Indirect By the Martha J. Demski Trust u/a 10/01/94
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on September 15, 2014.
  2. The range of sale prices received is $45.24 to $46.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares sold at each separate price.
  3. The range of sale prices received is $46.32 to $46.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares sold at each separate price.
  4. Immediately exercisable.